Skip to content
Open access

Targeting Problems and Adhering to Standards: A Pathway to Uniform Clinical Laboratory Processes that Maximize the Benefits of Pharmacogenomics.

Sep 2026 · Clinical pharmacology and therapy · 0 citations · 8 references
Medicine

TL;DR

Specific laboratory practices that should be discontinued or established and followed as standard practice are proposed and ideal practices that would advance pharmacogenomics in clinical care are proposed.

Abstract

Commercial laboratories often have differing approaches to pharmacogenomic testing, which detects the presence of germline genetic variants associated with drug response. Setting standards for clinical laboratories and defining criteria for clinicians to consider when choosing a testing laboratory can help maximize the benefits of pharmacogenomics. Here, we propose specific laboratory practices that should be discontinued or established and followed as standard practice. We also propose ideal practices that would advance pharmacogenomics in clinical care.

Read PDF

Similar papers

Open access Oct 2026

THE ROLE OF PHARMACOGENETICS IN PREDICTING DRUG RESPONSE AND ADVERSE DRUG REACTIONS

Give the same dose of the same drug to two patients, and one may be cured while the  other is harmed—a problem as old as prescribing itself. Much of that variability is  written in the genome. Pharmacogenetics, the study of how inherited variation modifies  drug response, has matured from a laboratory curiosity into a...

J. Sikarwar, Zunaira Amber, Nada Mohamme et al. · 0 citations
Open access Oct 2026

Advancing Therapeutics for Children with Medical Complexity: The Role of Model-Informed Precision Dosing and Genotype-Stratified Trials.

This work proposes a framework using genotype-stratified trials to characterize pharmacogenetic sources of variability, informing MIDD and MPID models while helping identify additional determinants of therapeutic response in CMC.

R. Gelineau-Morel, J. Leeder, Jonathan B. Wagner · 0 citations

AFFORDABLE PHARMACOGENOMICS IN

João Fernandes Floriano, Maria Elizabeth Menezes · 0 citations
Review Open access Sep 2026

[Clinical pharmacogenetics and the use of biobanks].

The Danish strategy for personalised medicine 2025-2027 includes initiatives for improving the use of pharmacogenetic information to guide drug therapy, and this review emphasises the need for improved infrastructure and data access for physicians.

M. Bentsen, J. Bundgaard, N. Brøns et al. · 0 citations
Review Open access Sep 2026

Clinical Pharmacogenomics: Translating Genetic Variation into Individualized Drug Therapy

Clinical pharmacogenomics (PGx) is an emerging component of precision medicine that examines how inherited genetic variation influences an individual's response to medicines. Genetic differences affecting drug-metabolizing enzymes, transporters, receptors, immune pathways and therapeutic targets can contribute to inter...

Kalyani R · 0 citations
Review Oct 2026

Pharmacogenetics in HIV therapy: a review of key biomarkers, regulatory annotations, and clinical dosing guidelines.

INTRODUCTION Pharmacogenetics is pivotal in modern HIV management, facilitating the transition from the traditional "one-size-fits-all" model toward personalized precision medicine. By analyzing how unique genetic profiles influence pharmacological responses, clinicians can maximize therapeutic efficacy while minimizin...

Rita Nogueiras-Álvarez · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.